NasdaqGS - Delayed Quote USD

Arbutus Biopharma Corporation (ABUS)

2.7200 -0.0300 (-1.09%)
At close: April 25 at 4:00 PM EDT
2.7300 +0.01 (+0.37%)
After hours: April 25 at 4:39 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Michael J. McElhaugh Co-Founder, Interim President, CEO & Director 644.4k -- 1975
Dr. Michael J. Sofia Ph.D. Chief Scientific Officer 656.1k -- 1958
Mr. David C. Hastings CPA CFO & Chief Accounting Officer 647.1k -- 1961
Ms. Lisa M. Caperelli Vice President of Investor Relations -- -- --
Mr. J. Christopher Naftzger BA, Esq., J.D. General Counsel, Chief Compliance Officer & Secretary -- -- 1967
Ms. Shannon Briscoe SPHR Vice President of Human Resources -- -- --
Dr. Karen Sims M.D., Ph.D. Chief Medical Officer -- -- 1971
Mr. R. Hector Mackay-Dunn B.A., J.D., L.L.B., Q.C. Corporate Secretary -- -- 1951

Arbutus Biopharma Corporation

701 Veterans Circle
Warminster, PA 18974
United States
267 469 0914 https://www.arbutusbio.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
73

Description

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

Corporate Governance

Arbutus Biopharma Corporation’s ISS Governance QualityScore as of April 1, 2024 is 6. The pillar scores are Audit: 3; Board: 6; Shareholder Rights: 9; Compensation: 6.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 02, 2024
Arbutus Biopharma Corporation Earnings Call

Related Tickers

ROIV Roivant Sciences Ltd.
10.88
-0.18%
 
ARWR Arrowhead Pharmaceuticals, Inc.
21.87
-6.10%
 
AFMD Affimed N.V.
4.8800
0.00%
 
GRTS Gritstone bio, Inc.
0.7645
-5.95%
 
ALNY Alnylam Pharmaceuticals, Inc.
143.71
-0.06%
 
PRQR ProQR Therapeutics N.V.
1.9600
-2.49%
 
ADAP Adaptimmune Therapeutics plc
1.0600
-1.85%
 
GERN Geron Corporation
3.5600
-0.56%
 
GALT Galectin Therapeutics Inc.
3.5000
+6.38%
 
ALDX Aldeyra Therapeutics, Inc.
3.9400
0.00%